Brooke McCormick

With the recent development of various new treatments, April Armstrong, MD, MPH, discusses the new standards she and other dermatologists hope to set for treating patients with atopic dermatitis (AD).

Compared with those without chronic obstructive pulmonary disease (COPD), patients with both sepsis and COPD had higher intensive care unit (ICU) mortality rates, longer ICU stays, and higher in-hospital mortality rates.

Amid National C. Diff Awareness Month, Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy, explains the foundation's "See C. diff" campaign and what the PLF hopes the public will learn throughout the month.

Natasha Halasa, MD, MPH, Vanderbilt University Medical Center, discusses the most pressing diarrheal illness challenges and successful strategies physicians can use to reduce this burden in patients.

High levels of phenotypic age acceleration (PhenoAgeAccel) were found to have a more significant effect on lung function in patients with chronic obstructive pulmonary disease (COPD), older patients, and White patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, lists barriers to care for dermatology patients.

Peter A. Lio, MD, clinical assistant professor of dermatology and pediatrics at Northwestern University's Feinberg School of Medicine, describes different methods dermatologists can use to treat atopic dermatitis (AD).

Robert Daly, MD, MBA, of Memorial Sloan Kettering Cancer Center, describes how new at-home treatment methods changed his delivery of care to patients with lung cancer.

Sara Horst MD, MPH, FACG, discusses recent improvements she helped make to the Vanderbilt University Medical Center's (VUMC) digital health systems and what changes she plans to help implement in the future.

Because of their study's findings, the researchers urged clinicians to screen patients with atopic dermatitis (AD) for cognitive dysfunction.

Despite e-cigarette use dropping 4.1% in the past year, it is still the most commonly used tobacco product among both middle and high school students.

Amy Laughlin, MD, MSHP, of Orlando Health gave a preview of the topic she is presenting on at today's American Journal of Managed Care®’s Institute for Value-Based Medicine® event in New York City.

Kathi Mooney, PhD, RN, FAAN, of the University of Utah, gave a preview of "The Oncology Hospital at Home," the presentation she is giving at The American Journal of Managed Care®’s Institute for Value-Based Medicine® event on November 2 in New York City.

Patients being unaware of their hepatitis C virus (HCV) infection is preventing the World Health Organization (WHO) from accomplishing its goal of eliminating HCV and hepatitis B virus as public threats by 2030.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed cost savings that occurred so far from their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health and also noted those they predict to occur as the program continues.

April Armstrong, MD, MPH, of University of California, Los Angeles, discussed how recent biologics advancements improved moderate-to-severe atopic dermatitis (AD) treatment.

The CDC found that the 2022-2023 influenza season had high severity among children and adolescents, resulting in them recommending that everyone receive the annual influenza vaccine by the end of October.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, provides an overview of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, discussing the program's origin, objectives, and beyond.

Posters presented at the American College of Gastroenterology's (ACG's) 2023 Annual Scientific Meeting examined potential environmental risks of eosinophilic esophagitis (EoE) on the pediatric population, as well as the presence of allergic comorbidities in children diagnosed with EoE.

April Armstrong, MD, MPH, of University of California, Los Angeles, gave an overview of her Fall Clinical Dermatology session on treating atopic dermatitis (AD) in patients with diverse skin tones and weighed in on how to address related treatment barriers.

Erin Gillaspie, MD, MPH, FACS, a faculty member of Vanderbilt University Medical Center’s (VUMC's) department of thoracic surgery, discussed trials that helped lung cancer surgeries evolve.

A poster presented at AMCP Nexus 2023 reported that payers believe implementing the Inflation Reduction Act (IRA) will impact Medicare Part D plans financially.

April Armstrong, MD, MPH, of University of California, Los Angeles, explained that the main health care gap within the atopic dermatitis (AD) realm is that many clinicians are not comfortable prescribing systemic medications.

Landon Marshall, PharmD, PhD, of Prime Therapeutics, discusses the benefits of gene therapy forecasting for health insurers and what future advancements can be expected.

Timothy O'Shea, PharmD, MS, discussed the most surprising findings from a home infusion pilot program and explained how he thinks home infusion will continue to evolve.

Christina Barrington, PharmD, of Priority Health, explained the keys to leading a successful managed care organization, as well as where she predicts the industry will be in the future.

Kimberly Maxfield, PhD, of the FDA reflected upon how the FDA is uplifting the US biosimilar industry.

Prerakkumar Parikh, PharmD, of Megallen Rx Management/Prime Therapeutics, detailed the impact of formulary placement of biosimilars on cost burden along with how stakeholders can work with pharmacy benefit managers to promote biosimilar use.

Saira Jan, PharmD, MS, of Horizon Blue Cross Blue Shield of New Jersey, discussed the primary findings of their collaborative pilot program with Rutgers Cancer Institute of New Jersey and RWJ Barnabas Health, focusing on patient and provider experiences.

Chelsee Jensen, PharmD, BCPS, of Mayo Clinic, commented on the recent FDA biosimilar approvals and what they mean for the industry's future, as well as how to ensure biosimilars are accessible to all patients.